Skip to main content
Equibles

UBS Group AG

Position in REPL — Replimune Group, Inc.

CIK 1610520 ZURICH, V8
Back to REPL Full portfolio

Position in REPL

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$12,490,015
+$8,043,760 QoQ
Shares Held
1,128,276
+94.1% QoQ
Ownership
1.20%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#20
of 199 holders
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in REPL Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,806 across 561 Biotechnology names. REPL ranks #103 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in REPL

Export CSV
25 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $12,490,015 1,128,276
2026-03-31 $4,446,255 581,210
2025-12-31 $5,873,921 604,313
2025-09-30 $3,777,829 901,630
2025-06-30 $2,261,158 243,397
2025-03-31 $1,445,973 148,305
2024-12-31 $1,155,863 95,447
2024-09-30 $997,545 91,017
2024-06-30 $209,043 23,227
2024-03-31 $3,006,445 367,986
2023-12-31 $1,858,199 220,427
2023-09-30 $1,025,624 59,943
2023-06-30 $643,982 27,734
2023-03-31 $1,494,282 84,614
2022-12-31 $1,617,339 59,461
2022-09-30 $113,169 6,553
2022-06-30 $491,135 28,097
2022-03-31 $1,603,472 94,433
2021-12-31 $1,705,294 62,926
2021-09-30 $817,649 27,586
2021-06-30 $310,164 8,073
2021-03-31 $1,361,508 44,625
2020-12-31 $101,288 2,655
2020-06-30 $164,556 6,622
2020-03-31 $402,169 40,338